Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Boston Therapeutics, Inc. (BTHE) Prepares For Third Phase Trial Of PAZ320 0 comments
    Jan 22, 2014 3:16 PM | about stocks: BTHE

    Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing, and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.

    PAZ320 is an integral part of the company's initial product pipeline, which is focused on developing and commercializing therapeutic molecules. PAZ320 is a non-systemic, non-toxic, chewable drug which inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.

    In November, Boston Therapeutics enrolled 24 patients with Type 2 diabetes in a Phase IIb clinical study on PAZ320, and positive results from the trial were published by the principal investigator in the July/August issue of the journal "Endocrine Practice". After evaluating the safety and efficacy of PAZ320, it was shown that there was a significant 40% reduction in elevation of post-meal blood glucose in the participating patients, with no serious adverse events.

    By the second or third quarter of 2014, the company hopes to begin an important Phase III trial of the chewable tablet it is promoting as a potential adjunct to metformin in patients living with Type 2 diabetes. While the Phase IIb trial was held only in France, the Phase III trial will be multi-national-in the United States, Europe, Hong Kong, and China.

    The company believes that PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need. The intent is for this compound to provide individuals with a means by which to slow the onset of Type 2 diabetes and/or the onset of diabetes complications such as heart disease, stroke, kidney damage, retinopathy, and Diabetic Foot.

    PAZ320 is meant to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.

    For more information about PAZ320 or any of the company's other products, visit the website at bostonti.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: BTHE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.